資料3

アンチバイオグラム 2018-2024
静岡県全体の経年変化

JANISデータは外来検体と比較した

Escherichia coli 大腸菌
Klebsiella pneumoniae subsp. Pneumoniae クレブシエラ菌
Streptococcus pneumoniae 肺炎球菌（髄液検体以外）
Streptococcus pyogenes 溶連菌
Haemophilus influenzae インフルエンザ菌
その他の情報：MRSA、VRE バンコマイシン耐性腸球菌

略称	一般名
PCG	ベンジルペニシリンカリウム
ABPC	アンピシリン水和物
CVA/AMPC	アモキシシリン水和物・クラブラン酸カリウム
CCL	セファクロル
CTX	セフォタキシムナトリウム
MEPM	メロペネム水和物
GM	ゲンタマイシン硫酸塩
LVFX	レボフロキサシン水和物
ST	スルファメトキサゾール・トリメトプリム
EM	エリスロマイシン
CAM	クラリスロマイシン
CLDM	クリンダマイシンリン酸エステル
FOM	ホスホマイシンナトリウム

データ提供施設数（カッコ内はクリニック）

	2018年	2019年	2020年	2021年	2022年	2023年	2024年
東部	16	17	19	16	15	15（3）	20（3）
中部	13	14	16	9	15	16（3）	18（4）
西部	14	14	14	8	13	15	22（0）
全体	40	45	49	33	43	46（6）	60（7）

腸内細菌目細菌の固有耐性

CLSI M100-ED33:2024 Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition **より引用**

Antimicrobial Agent → / Organism ↓	Ampicillin	Amoxicillin-clavulanate	Ampicillin-sulbactam	Ticarcillin	Cephalosporins I: Cefazolin, Cephalothin	Cephamycins: Cefoxitin, Cefotetan	Cephalosporins II: Cefuroxime	Imipenem	Tetracyclines	Tigecycline	Nitrofurantoin	Polymyxin B Colistin	Aminoglycosides
Citrobacter freundii	R	R	R		R	R	R						
Citrobacter koseri, Citrobacter amalonaticus group[a]	R			R									
Enterobacter cloacae complex[b]	R	R	R		R	R							
Escherichia coli	There is no intrinsic resistance to β-lactams in this organism.												
Escherichia hermannii	R			R									
Hafnia alvei	R	R	R		R	R						R[c]	
Klebsiella (formerly *Enterobacter*) *aerogenes*	R	R	R		R	R							
Klebsiella pneumoniae, Klebsiella oxytoca, Klebsiella varlicola	R			R									
Morganella morganii	R	R			R		R	[d]		R	R	R	
Proteus mirabilis	There is no intrinsic resistance to penicillins and cephalosporins in this organism.							[d]	R	R	R	R	
Proteus penneri	R				R		R	[d]	R	R	R	R	
Proteus vulgaris	R				R		R	[d]	R	R	R	R	
Providencia rettgeri	R	R			R			[d]	R	R	R	R	
Providencia stuartii	R	R			R			[d]	R	R	R	R	[e]
Raoultella spp.[f]	R			R									
Salmonella and *Shigella* spp.	There is no intrinsic resistance to β-lactams in these organisms; refer to **WARNING** below for reporting.												
Serratia marcescens	R	R	R		R	R	R				R	R	
Yersinia enterocolitica	R	R		R	R								

WARNING: For *Salmonella* spp. and *Shigella* spp., aminoglycosides, first– and second–generation cephalosporins, and cephamycins may appear active *in vitro* but are not effective clinically and should not be reported as susceptible.

Footnotes

a. *Citrobacter amalonaticus* group includes *C. amalonaticus*, *C. farmeri*, and *C. sedlakii*.

b. *E. cloacae* complex includes *Enterobacter asburiae*, *Enterobacter cloacae*, and *Enterobacter hormaechei*. Other members of the complex include *Enterobacter kobei* and *Enterobacter ludwigii*, for which antimicrobial susceptibility testing data are not available.

c. Colistin and polymyxin B resistance also applies to *Hafnia paralvei*.

d. *Proteus* spp., *Providencia* spp., and *Morganella* spp. may have elevated minimal inhibitory concentrations to imipenem by mechanisms other than by production of carbapenemases. Isolates that test as susceptible should be reported as susceptible.

e. *P. stuartii* should be considered resistant to gentamicin, netilmicin, and tobramycin but not intrinsically resistant to amikacin.

f. *Raoultella* spp. includes *R. ornithinolytica*, *R. terrigena*, and *R. planticola*.

NOTE 1: Cephalosporins III, cefepime, cefiderocol, aztreonam, ticarcillin–clavulanate, piperacillin–tazobactam, imipenem–relebactam, ceftazidime–avibactam, meropenem–vaborbactam, and the carbapenems are not listed because there is no intrinsic resistance in Enterobacterales.

NOTE 2: Enterobacterales are also intrinsically resistant to clindamycin, daptomycin, fusidic acid, glycopeptides (vancomycin), lipoglycopeptides (oritavancin, teicoplanin, telavancin), linezolid, tedizolid, quinupristin–dalfopristin, rifampin, and macrolides (erythromycin, clarithromycin, and azithromycin). However, there are some exceptions with macrolides (eg, *Salmonella* and *Shigella* spp. with azithromycin).

【*Escherichia coli*】　大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】　大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性







【*Escherichia coli*】　大腸菌

S:感受性、I:中間、R:耐性、NS:非感受性





CLSI M100-ED34:2024 Performance Standards for Antimicrobial Susceptibility Testing, 34rd Editionでは、大腸菌に対するFOMの判定基準は、尿路分離株のみに適応される。

【 *Klebsiella pneumoniae subsp. pneumoniae* 】 クレブシエラ菌

S:感受性、I :中間、R:耐性、NS:非感受性







【 *Klebsiella pneumoniae subsp. pneumoniae* 】 クレブシエラ菌

S:感受性、I :中間、R:耐性、NS:非感受性







肺炎球菌

【 *Streptococcus pneumoniae*（髄液検体以外）】

S：感受性、I：中間、R：耐性、NS：非感受性







肺炎球菌

【 *Streptococcus pneumoniae*（髄液検体以外）】

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Streptococcus pyogenes* 】 溶連菌

S:感受性、I :中間、R:耐性、NS:非感受性







【 *Streptococcus pyogenes*】　溶連菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】 インフルエンザ菌

S：感受性、I ：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】 インフルエンザ菌

S：感受性、I：中間、R：耐性、NS：非感受性







【 *Haemophilus influenzae* 】 インフルエンザ菌

S:感受性、I :中間、R:耐性、NS:非感受性



【 *Staphylococcus aureus* 】 **黄色ブドウ球菌（メチシリン耐性/感受性）**







【 静岡県内のVRE検出状況】

（グラフ作成にあたり、感受性結果が“ S ”以外（非感受性）を用いました）





【*Enterococcus faecium*（VRE）延べ55菌株の検出材料】

表中の数字は菌株数（重複検出を含む）

材料	東部	総計
糞便	31	31
カテーテル尿（採尿、留置カテの区別不能）	7	7
自然排尿	5	5
喀出痰	3	3
その他(泌尿・生殖)	3	3
胆汁	2	2
静脈血	2	2
採尿カテーテル尿	1	1
気管内採痰	1	1
菌株数（カッコ内は人数）	55（38）	55（38）